Search
Prucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. … Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties.
Categories: Serotonin Receptor Agonists, Serotonin-4 Receptor AgonistProducts: RESOLOR ® TABLETAS RECUBIERTAS DE 2 MG, RESOLOR ® TABLETAS RECUBIERTAS DE 1 MGIptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262581] This is of particular importance to PNH, where one of the disease hallmarks is the mutation of the PIGA gene. … [A262586] Additionally, iptacopan has the benefit of targeting factor B, which only affect the alternative complement pathway, leaving the classic and lectin pathway untouched for the body to still mount
Cystine
go.drugbank.com/drugs/DB00138ApprovedInvestigationalNutraceuticalWithdrawnA covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.
Azficel-T
go.drugbank.com/drugs/DB11051ApprovedWithdrawnAzficel-T is marketed in the US as Laviv for intradermal injection. … Azficel-T is an autologous cellular product composed of fibroblasts indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.
Synonyms: Azficel-TCryptenamine
go.drugbank.com/drugs/DB00785ApprovedCryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known. … It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects.
Paliperidone
go.drugbank.com/drugs/DB01267ApprovedInvestigationalPaliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. … It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Adrenergic alpha-1 Receptor AntagonistsProducts: INVEGA SUSTENNA® SUSPENSIÓN DE LIBERACIÓN PROLONGADA DE 25MG, INVEGASUSTENNA® SUSPENSIÓN DE LIBERACIÓN PROLONGADA DE 75 MGFilgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigational[A189165] Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.[L16616] … In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor.
Paltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigationalPaltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth … [A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061]
Categories: Somatostatin Receptor AgonistsBenzonatate
go.drugbank.com/drugs/DB00868Approved[A189519] It works to reduce the activity of cough reflex by desensitizing the tissues of the lungs and pleura involved in the cough reflex. … Benzonatate was approved by the FDA in 1958 under the market name Tessalon Perles.
Categories: Decreased Tracheobronchial Stretch Receptor ActivityDinutuximab
go.drugbank.com/drugs/DB09077ApprovedInvestigationalIt is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. … By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the